Healthcare
Press Release: Availability of the aide-mémoire for Q2 2026 results
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q2 2026 results will be published on July 30, 2026. About Sanofi Sanofi is an R&D
About this update from Sanofi Sa
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q2 2026 results will be published on July 30, 2026. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | [email protected] Evan Berland | +1 215 432 0234 | [email protected] Timothy Gilbert | +1 516 521 2929 | [email protected] Léo Le Bourhis | +33 6 75 06 43 81 | [email protected] Victor Rouault | +33 6 70 93 71 40 | [email protected] Léa Ubaldi | +33 6 30 19 66 46 | [email protected] Pesheva | +1 410 926 6780 | [email protected] Laura Romby| +33 6 74 16 74 29 | [email protected] Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | [email protected]é Kaisserian | +33 6 47 04 12 11 | [email protected] Browne | +1 781 249 1766 | [email protected] Pham | +33 7 85 93 30 17 | [email protected] Goworek | +1 908 569 7086 | [email protected] Châtelet | +33 6 80 80 89 90 | [email protected] Li | +33 6 84 00 90 72 | [email protected] Forward-looking statements This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. F...